Oncternal Therapeutics Inc. (ONCT) Tops Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Oncternal Therapeutics Inc. (ONCT) Tops Q2 EPS by 1c

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results

August 10, 2023 4:01 PM EDT

Obtained U.S. FDA IND clearance for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor signaling inhibitorsDosed the first patient in our Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for the treatment of patients with relapsed or refractory aggressive B-cell lymphomaCash runway extended into 2025, with $45.5 million in cash, cash equivalents and short-term investments and no debt as of June 30, 2023Management to host webcast today at 5:00 pm ET

SAN DIEGO, Aug. 10, 2023... More